TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Takeda Pharmaceutical Company (TAK β Research Report) and...
In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Axcella Health (AXLA - Research Report), with a price...
0001633070 false 0001633070 2022-09-29 2022-09-29 iso4217:USD xbrli:shares...
Axcella Therapeutics (NASDAQ:AXLA) shares are soaring in the pre-market session today on the back of positive interim data from the Phase 2b study...
UNITED STATES SECURITIESAND EXCHANGE COMMISSIONWashington, D.C.FORM DOMB APPROVALOMB Number: 3235-0076Estimated Average burden hours per...
0001633070 false 0001633070 2022-09-20 2022-09-20 iso4217:USD xbrli:shares...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
In a report released on August 12, Thomas Smith from SVB Securities maintained a Buy rating on Axcella Health (AXLA - Research Report), with a...
In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Axcella Health (AXLA - Research Report), with a price...
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Axcella Health (AXLA - Research Report) today and set a price target of $8.00. The...
2022Q2false0001633070--12-3100016330702022-01-012022-06-3000016330702022-08-09xbrli:shares00016330702022-06-30is...
0001633070FALSE00016330702022-08-122022-08-12UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 _____________________FORM...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.